<?xml version="1.0" encoding="UTF-8"?>
<akomaNtoso xmlns="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <act name="WKC">
    <meta>
      <identification source="#ny-legislature">
        <FRBRWork>
          <FRBRthis value="/akn/us-ny/act/wkc/section-13-P"/>
          <FRBRuri value="/akn/us-ny/act/wkc/section-13-P"/>
          <FRBRdate date="2017-04-21" name="enacted"/>
          <FRBRauthor href="#ny-legislature"/>
          <FRBRcountry value="us-ny"/>
          <FRBRnumber value="13-P"/>
          <FRBRname value="WKC"/>
        </FRBRWork>
        <FRBRExpression>
          <FRBRthis value="/akn/us-ny/act/wkc/section-13-P/eng@2025-12-31"/>
          <FRBRuri value="/akn/us-ny/act/wkc/section-13-P/eng@2025-12-31"/>
          <FRBRdate date="2025-12-31" name="publication"/>
          <FRBRauthor href="#arch"/>
          <FRBRlanguage language="eng"/>
        </FRBRExpression>
        <FRBRManifestation>
          <FRBRthis value="/akn/us-ny/act/wkc/section-13-P/eng@2025-12-31/main.xml"/>
          <FRBRuri value="/akn/us-ny/act/wkc/section-13-P/eng@2025-12-31/main.xml"/>
          <FRBRdate date="2025-12-31" name="generation"/>
          <FRBRauthor href="#arch"/>
        </FRBRManifestation>
      </identification>
      <references source="#arch">
        <TLCOrganization eId="arch" href="https://cosilico.ai" showAs="Cosilico Arch"/>
        <TLCOrganization eId="ny-legislature" href="https://legislation.nysenate.gov" showAs="New York State Legislature"/>
      </references>
    </meta>
    <body>
      <section eId="sec_13_P">
        <num>13-P</num>
        <heading>Comprehensive prescription drug formulary</heading>
        <content>
          <p>  ยง 13-p. Comprehensive prescription drug formulary. The chair shall\nestablish a comprehensive prescription drug formulary on or before\nDecember thirty-first, two thousand seventeen. The prescription drug\nformulary shall include a tiered list of high-quality, cost-effective\nmedications that are pre-approved to be prescribed and dispensed, as\nwell as additional non-preferred drugs that can be prescribed with prior\napproval. Such prescription drug formulary, shall include but not be\nlimited to implementation of a pharmacy reimbursement strategy,\nadministration of a prescription drug rebate program for formulary\ndrugs, a pre-approval program, drug utilization review, and limitations\non the prescribing of compounded medications and compounded topical\npreparations. The board shall promulgate regulations to permit an\ninterested party to submit a request to the medical director of the\nboard to alter or amend the formulary to consider changing the status of\na drug from non-preferred to preferred. Regulations may include a\nprovision for reasonable costs and fees associated with the review.\n</p>
        </content>
      </section>
    </body>
  </act>
</akomaNtoso>